Clinical Trials Browser

Completed × Gastrointestinal Neoplasms × trastuzumab deruxtecan × Clear all

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Phase 2 Completed

233 enrolled 26 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms